News ArchivesRead News
Stem cell transplant boosts function slightly in Parkinson's monkeys
Tuesday December 04, 2012
Los Angeles Times - In a small but hopeful step for researchers working on therapies to treat Parkinson’s disease, a team in Japan has used stem cells harvested from bone marrow to restore function in monkeys with the debilitating condition.
The cell transplants didn’t cure the macaques, but did improve motor skills in the animals and appeared to do so safely, the scientists wrote Monday in the Journal of Clinical Investigation — suggesting that stem cells from bone marrow might someday be a useful source for treatments of Parkinson’s in humans.
“To the best of our knowledge, this study is the first to show restoration of dopaminergic function and motor behaviors in parkinsonian primate animals” after treatment with stem cell-derived neurons, they wrote.
Stem cells are early-stage precursor cells that develop into the mature cells in the body. Scientists have long hoped to learn how to use them to replace cells and tissues damaged by accident or disease.
Parkinson’s has seemed like a good candidate for stem cell-derived therapies because people with the disorder have lost cells in the brain, or neurons, that produce the neurotransmitter dopamine. (For more about Parkinson’s read this page from the NIH’s National Institute of Neurological Disorders and Stroke.) If stem cells could be coaxed to develop into healthy, functioning dopaminergic neurons and then introduced into the brain, the thinking goes, perhaps patients could get relief from tremors, loss of balance and other debilitating Parkinson’s symptoms.
The Japanese team, led by Takuya Hayashi of the RIKEN Center for Molecular Imaging Science in Kobe, Japan, conducted its research on a group of 10 adult macaque monkeys. They induced Parkinson’s disease on the left side of the animals’ bodies.
They removed bone marrow from the hip bonesof the macaques, isolating so-called mesenchymal stem cells — the same type of cells that are sometimes harvested to treat patients with leukemia. (While mesenchymal stem cells can differentiate to become a variety of different types of cells including bone, cartilage and fat, they are not the same as embryonic stem cells or induced pluripotent stem cells, which can develop into any type of cell in the body.) The team used a previously reported method to turn the mesenchymal stem cells into dopamine-producing neurons.
Hayashi and his colleagues studied the neurons they created in the lab to assure that they were indeed dopamine-producing, and then administered treated cells to five of the monkeys. Each of the five monkeys received cells derived from his own bone marrow. The remaining monkeys received sham treatments.
Animals who received the cell treatments had improved motor function, the team reported. What’s more, through the use of PET scans and postmortem tissue analysis, the researchers determined that the implanted neurons continued producing small amounts of dopamine for at least nine months. The monkeys did not develop tumors, always a concern with stem-cell based therapies. Because the cells came from the monkeys’ own bone marrow, tissue rejection wasn’t an issue either. And the stem cells' origin in mature animals — not fetuses — sidestepped availability issues and ethical considerations involved in using fetal tissue, the scientists wrote.
Before the treatment might be considered appropriate for humans, they said, further studies will be needed to improve the viability of the cells once implanted, and to boost their therapeutic effect. But, they added, the approach “may expand the availability of cell sources for cell-based therapies for patients with Parkinson’s disease.”
Recent NewsMay 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis
Apr 12 - Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease
Apr 11 - Seattle boxing gym giving hope to Parkinson's patients
Apr 10 - A new rhythm
Apr 10 - Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapy
Apr 6 - FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Apr 5 - Combatting the isolation of young onset Parkinson's disease
Apr 1 - The Kid is Alright